<DOC>
	<DOCNO>NCT01895309</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , multicentre clinical study evaluate efficacy , safety , pharmacokinetics immunogenicity SB4 compare Enbrel subject moderate severe Rheumatoid Arthritis ( RA ) despite Methotrexate ( MTX ) therapy . In country , 52 week treatment either SB4 Enbrel , subject enrol open label extension period . Subjects receive SB4 additional 48 week .</brief_summary>
	<brief_title>A Study Comparing SB4 Enbrel® Subjects With Moderate Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosed RA accord revised 1987 ACR criterion least 6 month exceed 15 year prior Screening Have moderate severe active disease despite MTX therapy define equal six swollen joint equal six tender joint either erythrocyte sedimentation rate ( ESR , Westergren ) ≥ 28 mm/h serum Creactive protein ≥ 1.0 mg/dL Must treat MTX least 6 month prior Randomisation stable dose MTX 1025 mg/week give least 4 week prior Screening Female subject pregnant nursing Screening plan become pregnant Screening 2 month last dose investigational product Have treat previously biological agent include tumour necrosis factor inhibitor Have know hypersensitivity human immunoglobulin proteins component Enbrel SB4 Have positive serological test hepatitis B hepatitis C know history infection human immunodeficiency virus Have current diagnosis active tuberculosis Have serious infection treat intravenous antibiotic infection within 8 week oral antibiotic within 2 week prior Randomisation . Have follow condition 1 . Other inflammatory rheumatic disease . 2 . History malignancy within previous 5 year prior Screening 3 . History lymphoproliferative disease include lymphoma . 4 . History congestive heart failure 5 . Physical incapacitation ( ACR functional Class IV wheelchair/bedbound ) . 6 . History demyelinate disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Biosimilar</keyword>
</DOC>